The content on this site is intended for healthcare professionals only
Dr Claudio Cerchione speaks to ecancer about carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma. Initially, he talks about the background of the study.
Dr Cerchione then explains the methodology and results of the study. He concludes by discussing the impact of the results from this study can have on the future treatment of multiple myeloma.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Multiple myeloma in a resource constrained setting
Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia
Ide-cell enhances health-related quality of life for refractory multiple myeloma
